Quick Takes: And then there were two — bluebird readies for split

Bluebird bio Inc. (NASDAQ:BLUE) will officially split into two independent, publicly traded companies at close of business Tuesday, with each bluebird bio stockholder receiving a share of 2seventy bio Inc. stock for every three shares of bluebird stock held. The newco will trade on NASDAQ under the ticker “TSVT.”

Bluebird has been one of multiple companies to face safety setbacks for its gene therapies this year. After closing up shop in Europe, bluebird has regrouped on its home turf, where it  hopes to gain approval for its rare disease programs next year and has recently gained its first approval for a cancer program that is serving as an anchor for BMS’s oncology pipeline of partner Bristol Myers Squibb Co. (NYSE:BMY)...